Reversal Of Pulmonary Fibrosis After Gene Therapy Of Human | 2786
Journal of Community Medicine & Health Education
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Silicosis is a potentially fatal, irreversible pulmonary disease. The path physiology of silicosis is lung fibrosis induced by silica.
Hepatocyte growth factor (HGF) is a potent antifibrotic protein that inhibits pulmonary fibrosis. So HGF gene therapy may
be used in the treatment of silicosis. Here we show that pulmonary fibrosis of a patient with severe silicosis has been significantly
reversed at 6 months after HGF gene therapy. Naked HGF plasmid was transfected into mesenchymal stem cells (MSC) derived
from the patient. HGF-MSCs were resuspended in 50 ml 0.9% sodium chloride (NS) and infused to the patient. The symptoms
and pulmonary function significantly improved at 2m after HGF-MSCs infusion. Lung CT and high-kV chest X-ray showed
that silicon nodules had been partially absorpted at 5 months after treatment, better than before. No obvious discomfort after
treatment has been found till now. HGF can significantly enhance the lung collagenase activity, which can effectively degrade
collagen fibers, and our research proved that HGF gene therapy may be an effective and safe therapy for silicosis.
Chen Jiayu was born in August 1949, and is a Chief Physician. He graduating from Guangzhou Medical College. He acts as amember of the standing
committee of Guangdong province Cell Biology Society. His diagnosis and treatment with cell therapy for occupational disease, has reached the
leading domestic level.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals